NASDAQ:CRNX 26 September 2025

Crinetics (CRNX) shares jump as $350 million stock sale clears and early PALSONIFY revenue hits

Crinetics shares jumped 16% to $53.40 after the company priced a $350 million stock offering at $45.95 per share and reported over $5 million in preliminary Q4 revenue from newly launched PALSONIFY. The company also posted Phase 2 data for atumelnant in CAH, showing a 67% reduction in androstenedione and steroid tapering in most patients.

7 January 2026

Earnings Reports·NASDAQ:CRNX

Crinetics Pharmaceuticals (CRNX) Stock Drops After CMO Departure Filing: Latest News, Analyst Forecasts, and What’s Next (Dec. 18, 2025)

Crinetics Pharmaceuticals shares fell about 8% Thursday after a regulatory filing disclosed Chief Medical and Development Officer Dr. Dana Pizzuti will step down December 31. She will transition to a Strategic Regulatory and Development Advisor role in early 2026. The stock traded in the low-to-high $40s as investors reacted to the leadership change.

18 December 2025

NASDAQ:CRNX·Pharmaceuticals

Massive Moves: Record Deals, FDA Wins & Crypto Mania Propel Top Stock Gainers (Sep 29, 2025)

Electronic Arts shares jumped 15% after agreeing to a $55 billion buyout led by Saudi Arabia’s PIF, offering $210 per share. Crinetics Pharmaceuticals soared 28% as the FDA approved its oral acromegaly drug. QMMM Holdings surged 19% before the SEC halted trading over suspected manipulation. Scholar Rock gained 12% despite an FDA delay for its spinal atrophy drug.

29 September 2025

Cryptocurrency·NASDAQ:CRNX·NASDAQ:EA·NASDAQ:SRRK·NYSE:PPTA·Stock Market

Crinetics (CRNX) Stock Skyrockets on FDA Approval – Full 2025 Investor Update

Crinetics Pharmaceuticals shares surged 28% to around $46 on Sept. 26 after the FDA approved its first drug, Palsonify, for acromegaly. Trading volume spiked nearly tenfold amid heavy short-covering. The company plans to launch Palsonify in October at a $290,000 annual list price. Crinetics holds $1.2 billion in cash and no debt, with analysts raising price targets following the approval.

26 September 2025

NASDAQ:CRNX·Pharmaceuticals·Stock Market

Regeneus Ltd (RGS.AX) Jumps 33% on Heavy Volume, Signals Short-Term Upside
March 19, 2026, 10:42 PM EDT. Regeneus Ltd (RGS.AX) surged 33.33% to A$0.012 on March 20, 2026, driven by unusually heavy volume of 4.28 million shares, nearly seven times the average. The stock broke above its 50-day and 200-day moving averages, indicating increased short-term trader interest in this clinical-stage biotech focused on osteoarthritis and wound healing. Despite negative earnings per share and liquidity constraints, the price action reflects momentum trading in a volatile sector. Traders should watch intraday support at A$0.010 and resistance near the year high of A$0.020. With a Meyka AI rating of 64.90 (Grade B), the stock is rated HOLD amid high volatility and thin order books typical of small-cap biotechs on the Australian Securities Exchange (ASX).